Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabienne Thomas

Showing results (41-50 of 83) with videos related to

Pageof 9
Sort By:
Pharmaceuticals (Basel, Switzerland)|August 28, 2021
Cross-Validation of a Multiplex LC-MS/MS Method for Assaying mAbs Plasma Levels in Patients with Cancer: A GPCO-UNICANCER StudyClémence Marin, Nihel Khoudour, Aurélien Millet, et al.
Therapeutic Drug Monitoring|May 17, 2024
Model-Informed Precision Dosing of Intravenous Busulfan in Thai Pediatrics Undergoing Hematopoietic Stem Cell TransplantationApichaya Puangpetch, Fabienne Thomas, Usanarat Anurathapan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2007
Pilot study of neoadjuvant treatment with erlotinib in nonmetastatic head and neck squamous cell carcinomaFabienne Thomas, Philippe Rochaix, Adil Benlyazid, et al.
European Journal of Cancer (Oxford, England : 1990)|June 16, 2009
Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinomaFabienne Thomas, Philippe Rochaix, Melanie White-Koning, et al.
Cancer Chemotherapy and Pharmacology|January 2, 2021
Population pharmacokinetic and pharmacodynamic modeling of capecitabine and its metabolites in breast cancer patientsNastja Lunar, Marie-Christine Etienne-Grimaldi, Pauline Macaire, et al.
British Journal of Clinical Pharmacology|March 15, 2023
Discrepancies between dihydropyrimidine dehydrogenase phenotyping and genotyping: What are the explanatory factors?Capucine Arrivé, Xavier Fonrose, Fabienne Thomas, et al.
Clinical Chemistry and Laboratory Medicine|January 10, 2024
Impact of hemolysis on uracilemia in the context of dihydropyrimidine dehydrogenase deficiency testingGaspard Loison, Hélène Bouges Le Royer, Sabrina Marsili, et al.
Pharmacogenomics|August 13, 2015
Polymorphisms in SLCO1B3 and NR1I2 as genetic determinants of hematotoxicity of carboplatin and paclitaxel combinationLitaty Céphanoée Mbatchi, Antonin Schmitt, Fabienne Thomas, et al.
Seminars in Oncology|September 20, 2017
Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: The multiparametric approach is not convincingMarie-Christine Etienne-Grimaldi, Chantal Barin Le Guellec, Jean-Christophe Boyer, et al.
Cancer Letters|October 25, 2024
Tumor-associated macrophages confer resistance to chemotherapy (Trifluridine/Tipiracil) in digestive cancers by overexpressing thymidine phosphorylaseMarie Malier, Marie-Hélène Laverriere, Maxime Henry, et al.
Pageof 9

Showing results (41-50 of 83) with videos related to

Sort By:
Pageof 9
Pharmaceuticals (Basel, Switzerland)|August 28, 2021
Cross-Validation of a Multiplex LC-MS/MS Method for Assaying mAbs Plasma Levels in Patients with Cancer: A GPCO-UNICANCER StudyClémence Marin, Nihel Khoudour, Aurélien Millet, et al.
Therapeutic Drug Monitoring|May 17, 2024
Model-Informed Precision Dosing of Intravenous Busulfan in Thai Pediatrics Undergoing Hematopoietic Stem Cell TransplantationApichaya Puangpetch, Fabienne Thomas, Usanarat Anurathapan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2007
Pilot study of neoadjuvant treatment with erlotinib in nonmetastatic head and neck squamous cell carcinomaFabienne Thomas, Philippe Rochaix, Adil Benlyazid, et al.
European Journal of Cancer (Oxford, England : 1990)|June 16, 2009
Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinomaFabienne Thomas, Philippe Rochaix, Melanie White-Koning, et al.
Cancer Chemotherapy and Pharmacology|January 2, 2021
Population pharmacokinetic and pharmacodynamic modeling of capecitabine and its metabolites in breast cancer patientsNastja Lunar, Marie-Christine Etienne-Grimaldi, Pauline Macaire, et al.
British Journal of Clinical Pharmacology|March 15, 2023
Discrepancies between dihydropyrimidine dehydrogenase phenotyping and genotyping: What are the explanatory factors?Capucine Arrivé, Xavier Fonrose, Fabienne Thomas, et al.
Clinical Chemistry and Laboratory Medicine|January 10, 2024
Impact of hemolysis on uracilemia in the context of dihydropyrimidine dehydrogenase deficiency testingGaspard Loison, Hélène Bouges Le Royer, Sabrina Marsili, et al.
Pharmacogenomics|August 13, 2015
Polymorphisms in SLCO1B3 and NR1I2 as genetic determinants of hematotoxicity of carboplatin and paclitaxel combinationLitaty Céphanoée Mbatchi, Antonin Schmitt, Fabienne Thomas, et al.
Seminars in Oncology|September 20, 2017
Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: The multiparametric approach is not convincingMarie-Christine Etienne-Grimaldi, Chantal Barin Le Guellec, Jean-Christophe Boyer, et al.
Cancer Letters|October 25, 2024
Tumor-associated macrophages confer resistance to chemotherapy (Trifluridine/Tipiracil) in digestive cancers by overexpressing thymidine phosphorylaseMarie Malier, Marie-Hélène Laverriere, Maxime Henry, et al.
Pageof 9